—Total Company Revenues of $425.5 Million for the Second Quarter of 2026—
Barchart Research What to Expect from INSM Earnings INSM Generated August 5, 2026 Current Price $99.02 EPS Estimate $$-0.69 Consensus Rating Strong Buy Average Move 7.20% Can Insmed's Revenue Growth Mask...
BRIDGEWATER, N.J. , July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
After a second quarter that saw the index rally around 15%, following a first quarter in which it lost more than 4%, the playing field has been left with a scattered group of winners and losers.
BRIDGEWATER, N.J. , June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.
CoreWeave stock has been included in the illustrious Nasdaq 100 club starting June 22.
The S&P 500 Index ($SPX ) (SPY ) on Friday rose +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) rose +0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.64%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) is up +0.58%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.91%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.64%. June E-mini S&P futures (ESM26 ) are...